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ABSTRAK
Gen penindas p53 dan proto-onkogen Bcl-2 mengkodkan fosfoprotin nuklear 
dan protin membran mitokondria yang terlibat dalam pelbagai fungsi sel. Kedua-
dua protin mempunyai hubung kait dengan tapak jalan kematian sel berprogram 
disamping memberi informasi prognostik karsinoma payudara. Objektif kajian 
ini adalah untuk menentukan kaitan onko-protin p53 dan Bcl-2 pada karsinoma 
payudara dan hubungannya dengan umur pesakit, saiz tumor, peringkat kanser 
dan gred histologi. Lima puluh sembilan kes kanser payudara dari Pusat Perubatan 
Universiti Kebangsaan Malaysia (PPUKM) telah dikaji menggunakan teknik 
imunohistokimia. Keputusan menunjukkan 45.8% (27/59) kanser payudara adalah 
imunopositif untuk p53 dan 40.7% (24/59) adalah imunopositif untuk Bcl-2. Terdapat 
korelasi signifikan di antara ekspresi Bcl-2 dengan peringkat awal kanser (p=0.01). 
Variabel lain tidak menunjukkan kaitan signifikan. Kaitan songsang didapati di 
antara p53 dan Bcl-2 (p=0.001). Hasil keputusan mencadangkan regulasi menurun 
Bcl-2 oleh p53 dalam karsinogenesis kanser payudara.
Kata kunci: korelasi songsang, p53,Bcl-2, karsinoma payudara, regulasi menurun
ABSTRACT 
The tumour suppressor gene p53 and the proto-oncogene Bcl-2 encode respectively, 
for a nuclear phosphoprotein and for a mitochondrial membrane protein involved 
in multiple cellular functions. Both proteins are linked to programmed cell death 
pathways and provide prognostic information on breast carcinoma. Our aim is 
to study the expression of p53 and Bcl-2 oncoproteins in breast carcinoma and 
correlate with patients’ age, tumour size, disease stage and histological grade. Fifty 
nine  cases of breast carcinomas from Universiti Kebangsaan Malaysia Medical 
Centre (UKMMC) were studied with the immunohistochemical method. Our results 
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showed 45.8% (27 of 59) and 40.7% (24 of 59) of the breast carcinomas were 
immunopositive for p53 and Bcl-2 respectively. There was significant correlation 
between Bcl-2 expression with early tumour stage (p=0.01). No significant 
relationship was seen with other variables. Results also showed an inverse 
relationship between p53 and Bcl-2 expression (p=0.001). These findings indicate a 
down regulation of Bcl-2 by p53 in breast carcinogenesis. 
Keywords: inverse correlation, p53,Bcl-2, breast carcinoma, downregulation
 The p53 gene is a tumour suppressor 
gene which is located on the short arm 
of chromosome 17 at 17p13.1. It encodes 
the 53kDa nuclear phosphoprotein 
expressed by normal cells and contains 
many important biological functions. 
This includes growth and cellular 
transformation, cell cycle and genomic 
stability. It also regulates apoptosis 
which is important after DNA damage. 
Abnormalities identified in the p53 
tumour suppressor gene are some of the 
molecular incidences seen in human 
and animal neoplasms (Hainaut et al. 
1998). P53 is involved in regulation of 
cell proliferation, directing apoptosis 
and promoting chromosomal stability. 
Any disturbances in these functions 
play an important role in carcinogenesis 
(Levine 1997). Changes in the p53 gene 
cause it to lose its functions as a cell 
growth regulator.
 Somatic mutation of p53 is one of 
the molecular abnormalities which is 
frequently seen in carcinoma (Coles et 
al. 1992; Osborne et al. 1991). Previous 
studies have shown that somatic gene 
mutation of p53 was present in 30% to 
50% of breast carcinoma. It has been 
proven that protein overexpression of 
mutant p53 gene is associated with a 
poor response towards chemotherapy 
and poor prognosis in patients with 
INTRODUCTION 
In Malaysia, breast cancer is the 
commonest cancer in all ethnic 
groups, accounting for 30.4% of newly 
diagnosed cancer cases in Malaysian 
women (Lim et al. 2003). The incidence 
of breast carcinoma increases from year 
to year and the risk rises with increasing 
age.
 Until now, the true aetiology of 
breast carcinoma is still unknown. 
However, studies have shown that it is 
a multifactorial and multigenic disease. 
Genetic factors are one of the risk factors 
that have been identified or believed to 
cause breast carcinoma. Several studies 
have been done to identify the role of 
biologic tumour markers in predicting 
response towards treatment of breast 
carcinoma. Of all the biologic tumour 
markers that have been identified, the 
relationship between p53 and bcl-2 
protein expression has become the 
focus of attention.
 Breast carcinogenesis involves 
at least one initiation stage and 
promotion or progression stage. It 
can be associated with epigenetic 
alterations and genetic response which 
controls gene regulation. Among these 
alterations, deactivation of p53 gene is 
considered the most common genetic 
change (Schmitt et al. 1995).
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breast carcinoma (Davidoff et al. 1991; 
Kovach et al. 1996; Isola et al. 1992; 
Silvestrini et al. 1993; Thor et al. 1992).
Bcl-2 is a human proto-oncogene 
and is located on chromosome 
18 at 18q21. Bcl-2 produces the 
membrane integral protein which is 
located on the endoplasmic reticulum 
membrane, nuclear envelope and outer 
mitochondrial membrane. The location 
of Bcl-2 suggests that it may be involved 
in some of the pathways of metabolic 
function of mitochondrial membrane 
(Hockenbery et al. 1990).
 Bcl-2 was first discovered in follicular 
and diffuse lymphomas possessing 
t(14;18) chromosomal translocation 
and has been established as a key 
regulator of apoptosis (Kroemer 1997). 
A decreased expression of Bcl-2 protein 
was shown to be associated with a 
poor clinical outcome in breast cancer 
(Silvestrini et al. 1994; Joensuu et al. 
1994; Gasparini et al. 1995).
 An inverse relationship between 
p53 and Bcl-2 has been shown in 
primary breast carcinomas, and the 
two oncoproteins may interact in the 
regulation of apoptosis (Silvestrini 
et al. 1994; Gasparini et al. 1995; 
Barbareschi et al. 1996). Recently, p53 
has been shown to be inactivated 
by alterations other than mutation of 
TP53 itself (Abdel-Fatah et al. 2010). 
More importantly, completely inactive 
p53 pathway exhibited unfavorable 
clinicopathologic features, bad 
prognosis and poor outcome despite 
receiving systemic adjuvant therapy 
(Abdel-Fatah et al. 2010). However, 
studies investigating the relationship 
between p53 and Bcl-2 have mainly 
been in breast cancers involving the 
western population. To date, there 
have been no studies performed on the 
significance of p53 and Bcl-2 expression 
in breast carcinomas in Malaysian 
women.
 Based on these observations, we 
aim to study the expression of p53 and 
one of its downstream genes, Bcl-2 
and its role in tumorigenesis of breast 
carcinomas in Malaysian patients. 
We also aim to correlate the findings 
with other prognostic variables and 
clinicopathological data.
MATERIALS AND METHODS
Breast Cancer Specimens
This is a retrospective study utilising 
paraffin embedded tissue (PET) blocks 
from 59 cases of breast carcinomas 
(53 infiltrating ductal carcinoma, 2 
ductal carcinoma in situ, 2 mucinous 
carcinoma, 1 squamous cell carcinoma, 
1 papillary carcinoma) at Universiti 
Kebangsaan Malaysia Medical Centre 
(UKMMC). This study was approved 
by the Ethics Committee of UKMMC. 
Clinical data of the patients were 
obtained from the Medical Records 
Unit, UKMMC. Only cases with 
complete medical data were selected. 
Haematoxylin and eosin stained slides 
from the tumour of each of the cases 
were reviewed. Sequential sections for 
further immunohistochemical studies 
were determined after selection of the 
appropriate tumour section. 
Immunohistochemical Study
Three µm thick sequential sections 
from PET blocks were cut and placed 
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on poly-L lysine coated slides. The 
slides were then placed in an oven for 
30 minutes at 55˚C. The tissue sections 
were then dewaxed in xylene and 
rinsed in graded alcohol. Endogenous 
peroxidase was blocked by incubation 
in 3% hydrogen peroxide. Subsequently 
the slides were rinsed in running water 
before being subjected to Target 
Retrieval Solution for 20 minutes 
at 97˚C. For p53 staining, a Target 
Retrieval Solution of normal pH was 
used while a high pH was used for Bcl-
2 staining. The slides were then allowed 
to cool for 20 minutes and washed 
in TBS. The primary antibody is then 
dropped onto the tissue sections before 
being incubated for 30 to 60 minutes, 
followed by a rinse in TBS. The slides are 
then incubated for 15 minutes with link 
antibody. Subsequently streptavidin and 
peroxidase were applied for 15 minutes. 
The immunoprecipitate was visualized 
by treating with Diaminobenzidine 
(DAB) and counterstaining with 
haematoxylin.
Controls 
Known p53 and Bcl-2 positive breast 
carcinomas were used as positive 
controls for p53 and Bcl-2 respectively. 
Negative controls were run with each 
batch by replacing the primary antibody 
with normal saline.
Interpretation of Results and 
Staining Characteristics
Each case was assessed by two 
observers without the knowledge of 
patient’s clinical data. The tumour cells 
showed positive nuclear staining with 
p53. Cases were considered positive for 
each marker when at least 5% of the 
cells showed positive staining with the 
relevant antibody (Poller et al. 1993).
 Positive Bcl-2 staining was 
cytoplasmic and tissue sections 
showing less than 10% of the cells 
with positive staining were considered 
negative (Simon & Altman 1994).
Statistical Analysis
The relationship between Bcl-2 and 
p53 immunostaining, and with other 
clinicopathological variables were 
evaluated using the X2-test. Statistical 
procedures were performed using 
the SPSS software version 10.0.1. The 
statistical significance was defined as 
p<0.01.
RESULTS
Twenty seven of 59 (45.7%) of the 
cases showed p53 immunopositivity 
(Table 1, Figure 1). Heterogenous and 
homogenous distribution pattern were 
seen with p53 nuclear staining. Eleven 
out of 27 cases showed heterogenous 
distribution of p53 immunostaining 
while 16 cases showed homogenous 
distribution pattern.  Both nuclear and 
cytoplasmic staining were seen in four 
cases.
 Twenty four of 59 (40.7%) of the 
cases showed Bcl-2 immunopositivity 
(Table 2, Figure 2). The distribution 
pattern for Bcl-2 immunostaining was 
mostly homogenous. However, five 
out of 24 cases showed heterogeneous 
distribution pattern of Bcl-2 
immunostaining. Bcl-2 immunostaining 
was also present in the normal breast 
epithelial cells adjacent to the tumour 
cells in five cases.
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 Results also showed a significant 
inverse relationship between p53 
and Bcl-2 protein expressions in the 
tumours studied (X2=10.130b, df=2, 
p=0.001). Thirteen of 59 (22%) cases 
are immunonegative for both p53 
and Bcl-2. Only five cases were 
immunopositive for both p53 and Bcl-
2 proteins. Twenty two cases (37.3%) 
were immunopositive for p53 and 
immunonegative for Bcl-2. Nineteen 
cases (32.2%) were immunopositive 
for Bcl-2 and immunonegative for 
p53 (Table 3). Neither p53 nor Bcl-
2 expression showed any significant 
correlation with tumour size, age and 
histologic grade (Table 4). 
 There was no association seen 
between p53 expression and individual 
disease stage (Table 5). On the contrary, 
a significant association was found 
between Bcl-2 expression and early 
stage of disease (Stage 0, I, II). Six of 
seven (85.7%) patients with early stage 
disease showed Bcl-2 immunopositivity 
(p=0.01) while only 34.6% of patients 
with late stage disease (stage III, IV) 
showed Bcl-2 immunopositivity (Table 
6).
DISCUSSION
p53 and Bcl-2 are known to be involved 
in the regulation of apoptosis and have 
Table 1: Frequency of p53 
expression in breast carcinoma 
(n=59) 
P53 expression Frequency (%)
   Positive 27 (45.8)
Table 2: Frequency of Bcl-2 
expression in breast carcinoma 
(n=59)
Bcl-2 expression Frequency (%)
Positive 24 (40.7)
Negative 35 (59.3)
Table 3: p53 and Bcl-2 expressions 
in Breast Carcinoma (n=59)
Bcl-2 
expression
P53 expression
P
Negative Positive
Negative 13 (22%) 22 (37.3%) 0.001
Positive 19 (32.2%) 5 (8.5%) 0.001
Figure 1. Histological section of IDC 
showed immunopositivity for Bcl-2 in the 
cytoplasm (magnification x400)
Figure 2. Histological section of IDC 
showed strong immunopositivity for p53 
in the nucleus (magnification x400)
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been investigated widely in neoplasms 
(Silvestrini et al. 1994; Watson et al. 
1996). The loss of p53 function represents 
the most common genetic change 
in human neoplasms. Experimental 
studies have demonstrated Bcl-2 to be 
implicated in regulating the cell cycle 
and proliferation (Watson et al. 1996; 
Bonnefoy-Berard et al. 2004). Both p53 
and Bcl-2 are expressed in breast cancer 
and have been shown to associate 
with a series of clinicopathological 
parameters (Watson et al. 1996). 
However, the relationship between 
p53 and Bcl-2 expression and their role 
in breast tumorigenesis in Malaysian 
patients has not been reported.
In this present study, there is an 
overexpression of p53 in 45.8% of 
the cases. This is consistent with the 
findings of other previous studies for 
which the range was between 16% to 
58% (Davidoff et al. 1991; Isola et al. 
1992; Thor et al. 1992; Bartek et al. 
1990; Molina et al. 1998; Allred et al. 
1993). The variation of p53 expression 
in the different studies is probably 
attributed by the number of samples 
studied, preferred methodology and 
the types of antibody that was used.
Studies of p53 expression on ductal 
carcinoma in situ (DCIS) are limited 
(Davidoff et al. 1991; Thor et al. 1992; 
Poller et al. 1993; Walker et al. 1991). 
In our study, one of the two DCIS 
cases showed positive expression of 
p53. This finding is in keeping with 
previous studies and supports the idea 
Table 4: Correlation between p53 and Bcl-2 expressions and clinicopathologic 
characteristics of breast carcinoma
Clinicopathologic 
characteristics
No of Bcl-2 
positive cases (%) P
No of p53- positive 
cases (%) P
Age (yr)
<50 12 (36.3) 0.447 16 ( 48.4) 0.636
>50 12 (46.1) 11 (42.3)
Tumour size (cm)
< 2 3 (50) 0.717 5 (83.3) 0.06
>2 16 (53.3) 16 (42.1)
Histologic Grade
Grade 1 8 (57.1) 0.286 5 (35.7) 0.531
Grade 2 5 (33.3) 7 (46.7)
Grade 3 5 (31.3) 9 (56.3)
Table 5: P53 expression with Stage 
of Disease (n=59)
Stage of Disease
P53 expression
Negative Positive
Early (0, I, II) 5 (71.4%) 2 (28.6%)
Late   (III, IV) 27 (51.9%) 25 (48.1%)
p=0.331
Table 6:  Bcl-2 expression with 
Stage of Disease (n=59) 
Stage of Disease
Bcl-2 expression
Negative Positive
Early (0, I, II) 1 (14.3%) 6 (85.7%)
Late (III, IV) 34 (65.4%) 18 (34.6%)
p=0.01
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that abnormal p53 protein is implicated 
in the early development of breast 
carcinomas (Walker et al. 1991).
 We also found that Bcl-2 expression 
was present in 40.7% of the cases. This 
finding is in keeping with the findings 
of other previous studies for which the 
range of expression varies between 
38.7% and 81.2% (Joensuu et al. 1994; 
Charpin et al. 1998; Berardo et al. 1998; 
Coppola et al. 1999). The variation of 
Bcl-2 expression in the different studies 
is probably attributed by tissue sampling 
(paraffin or frozen section), method of 
analysis, and the positive cut- off point. 
In this study, Bcl-2 expression was 
identified in almost all of the normal 
breast epithelia adjacent to the 
tumours. This suggests that Bcl-2 
expression is required to protect normal 
breast epithelial cells from apoptosis 
and ensure the survival of the breast 
epithelium (Zhang et al. 1997).
 Both of the DCIS cases in our 
study had shown Bcl-2 expression 
whereas only 35.8% of the invasive 
breast carcinomas had shown Bcl-2 
expression. A significant decrease in Bcl-
2 expression was observed during the 
evolution from normal breast epithelial 
cells to ductal carcinoma in situ (DCIS) 
and from DCIS to invasive breast 
carcinomas. This present result indicates 
that the reduction in Bcl-2 expression 
is associated with carcinogenesis and 
progression of breast carcinoma. This 
phenomenon was also reported in 
other studies (Zhang et al. 1997; Leek 
et al. 1994). The down regulation of 
Bcl-2 is necessary to induce apoptosis 
of cancer cells for the maintenance 
of increased cell turnover and the 
balance between tumour growth and 
apoptosis. Although we could not find 
any significant correlation between 
Bcl-2 expression and DCIS due to the 
limited number of DCIS cases studied, 
our findings suggest that DCIS may 
share smilar molecular pathways to 
that of an invasive carcinoma. Of note, 
the lack of Bcl-2 expression was seen 
more in recurrent DCIS (Provenzona 
et al. 2003), suggesting the role of Bcl-
2 in the progression and malignant 
transformation of DCIS.
 The present study had demonstrated 
a significant inverse correlation 
between p53 and Bcl-2 expressions in 
breast carcinoma. A significant inverse 
correlation was also demonstrated in 
other studies (Kroemer 1997; Silvestrini 
et al. 1994; Joensuu et al. 1994; Gasparini 
et al. 1995; Barbareschi et al. 1996) 
while no correlation was found in others 
(Bonnefoy-Berard et al. 2004; Nohara 
et al. 2001; Lau et al. 2001; Sgambato 
et al. 2000). Haldar and colleagues 
had shown that the overexpression of 
mutant p53 in breast cancer (MCF-7) 
cell line induced the down regulation 
of Bcl-2 at both the protein and mRNA 
levels (Haldar et al. 1994).
 We have also demonstrated that 
37% of p53 immunopositive breast 
cancer were Bcl-2 immunonegative. 
In addition, we have also found that 
lack of Bcl-2 expression was also more 
associated with tumours of late stage. 
A combination of p53 overexpression 
and lack of Bcl-2 expression was more 
likely to be seen in aggressive tumours 
with reduced five year survival (Rolland 
et al. 2007).
 In this study, there is a significant 
correlation between Bcl-2 expression 
and early tumour stage of the disease 
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in which the tumours tend to be better 
differentiated. A relative reduction of Bcl-
2 expression in the late stages of breast 
carcinoma suggests a downregulation 
of Bcl-2 with tumour development. 
This finding indicates that Bcl-2 
expression in early breast carcinoma is 
associated with a good prognosis. Our 
results are in accordance with a study 
done by Leek et al. (1994) who had 
reported that loss of Bcl-2 expression 
was associated with poor outcome and 
that its expression was associated with 
improved survival (Berardo et al. 1998, 
Callagy et al. 2006). Bcl-2 has also been 
shown to be a powerful independent 
prognostic marker for patients with 
early breast cancer independent of 
adjuvant therapy (Dawson et al. 2010).
CONCLUSION
The present study demonstrated an 
inverse relationship between p53 and 
Bcl-2 protein expressions indicating 
that overexpression of mutant p53 
induces downregulation of Bcl-2 in 
breast carcinogenesis. Our results also 
demonstrated that Bcl-2 is expressed 
in the early stages of breast cancer. 
The combined Bcl-2 overexpression 
and loss of p53 expression are useful 
markers in predicting good prognostic 
outcome in patients with breast cancer.
REFERENCES
Abdel-Fatah, T.M., Powe, D.G., Agboola, J., 
Adamowicz-Brice, M., Blamey, R.W., Lopez-
Garcia, M.A., Green, A.R., Reis-Filho, J.S. & 
Ellis, I.O. 2010. The biological, clinical and 
prognostic implications of p53 transcriptional 
pathways in breast cancers. J Pathol 220(4): 
419-434.
Allred, D.C., Clark, G.M., Elledge, R., Fuqua, S.A., 
Brown, R.W., Chamness, G.C., Osborne, C.K. & 
Mcguire, W.L. 1993. Association of p53 protein 
expression with tumor cell proliferation rate 
and clinical outcome in node-negative breast 
cancer. J Natl Cancer Inst 85(3): 200-206.
Barbareschi, M., Caffo, O., Veronese, S., Leek, R.D., 
Fina, P., Fox, S., Bonzanini, M., Girlando, S., 
Morelli, L., Eccher, C., Pezzella, F., Doglioni, C., 
Dalla Palma, P. & Harris, A. 1996. Bcl-2 and p53 
expression in node-negative breast carcinoma: 
a study with long-term follow-up. Hum Pathol 
27(11): 1149-1155.
Bartek, J., Bartkova, J., Vojtesek, B., Staskova, Z., 
Rejthar, A., Kovarik, J. & Lane, D.P. 1990. 
Patterns of expression of the p53 tumour 
suppressor in human breast tissues and tumours 
in situ and in vitro. Int J Cancer. 46(5): 839-844.
Berardo, M.D., Elledge, R.M., De Moor, C., Clark, 
G.M., Osborne, C.K. & Allred, D.C. 1998. bcl-
2 and apoptosis in lymph node positive breast 
carcinoma. Cancer 82(7): 1296-1302.
Bonnefoy-Berard, N., Aouacheria, A., Verschelde, 
C., Quemeneur, L., Marcais, A. & Marvel, J. 
2004. Control of proliferation by Bcl-2 family 
members. Biochim Biophys Acta. 1644(2-3): 
159-168
Charpin, C., Garcia, S., Bonnier, P., Martini, F., 
Andrac, L., Horschowski, N., Lavaut, M.N. 
& Allasia, C. 1998. bcl-2 automated and 
quantitative immunocytochemical assays in 
breast carcinomas: correlation with 10-year 
follow-up. J Clin Oncol 16(6): 2025-2031.
Coles, C., Condie, A., Chetty, U., Steel, C.M., Evans, 
H.J. & Prosser, J. 1992. p53 mutations in breast 
cancer. Cancer Res 52(19): 5291-5298.
Coppola, D., Catalano, E. & Nicosia, S. V. 1999. 
Significance of p53 and Bcl-2 Protein Expression 
in Human Breast Ductal Carcinoma. Cancer 
Control 6(2): 181-187. 
Davidoff, A. M., Kerns, B. J., Iglehart, J. D. & Marks, 
J. R. 1991. Maintenance of p53 alterations 
throughout breast cancer progression. Cancer 
Res 51(10): 2605-2610.
Gasparini, G., Barbareschi, M., Doglioni, C., Palma, 
P.D., Mauri, F.A., Boracchi, P., Bevilacqua, P., 
Caffo, O., Morelli, L., Verderio, P. & Et Al. 1995. 
Expression of bcl-2 protein predicts efficacy of 
adjuvant treatments in operable node-positive 
breast cancer. Clin Cancer Res 1(2): 189-198.
Hainaut, P., Hernandez, T., Robinson, A., Rodriguez-
Tome, P., Flores, T., Hollstein, M., Harris, C.C. & 
Montesano, R. 1998. IARC Database of p53 gene 
mutations in human tumors and cell lines: updated 
compilation, revised formats and new visualisation 
tools. Nucleic Acids Res 26(1): 205-213.
Haldar, S., Negrini, M., Monne, M., Sabbioni, S. & 
Croce, C. M. 1994. Down-regulation of bcl-2 
by p53 in breast cancer cells. Cancer Res 54(8): 
2095-2097.
Hockenbery, D., Nunez, G., Milliman, C., Schreiber, 
R. D. & Korsmeyer, S. J. 1990. Bcl-2 is an inner 
40
Med & Health 2012; 7(1): 32-40 Mdzin R. et al.
mitochondrial membrane protein that blocks 
programmed cell death. Nature. 348(6299): 
334-336.
Isola, J., Visakorpi, T., Holli, K. & Kallioniemi, O. 
P. 1992. Association of overexpression of 
tumor suppressor protein p53 with rapid cell 
proliferation and poor prognosis in node-
negative breast cancer patients. J Natl Cancer 
Inst 84(14): 1109-1114.
Joensuu, H., Pylkkanen, L. & Toikkanen, S. 1994. Bcl-
2 protein expression and long-term survival in 
breast cancer. Am J Pathol 145(5): 1191-1198.
Kovach, J.S., Hartmann, A., Blaszyk, H., Cunningham, 
J., Schaid, D. & Sommer, S.S. 1996. Mutation 
detection by highly sensitive methods indicates 
that p53 gene mutations in breast cancer can 
have important prognostic value. Proc Natl 
Acad Sci USA 93(3): 1093-6.
Kroemer, G. 1997. The proto-oncogene Bcl-2 and its role 
in regulating apoptosis. Nat Med 3(6): 614-620.
Lau, R., Grimson, R., Sansome, C., Tornos, C. & Moll, 
U. M. 2001. Low levels of cell cycle inhibitor 
p27kip1 combined with high levels of Ki-67 
predict shortened disease-free survival in T1 
and T2 invasive breast carcinomas. Int J Oncol 
18(1): 17-23.
Leek, R.D., Kaklamanis, L., Pezzella, F., Gatter, K.C. & 
Harris, A. L. 1994. bcl-2 in normal human breast 
and carcinoma, association with oestrogen 
receptor-positive, epidermal growth factor 
receptor-negative tumours and in situ cancer. 
Br J Cancer. 69(1): 135-139.
Levine, A. J. 1997. p53, the cellular gatekeeper for 
growth and division. Cell 88(3): 323-331.
Lim, G.C.C., Yahaya, H. & Lim, T.O. 2003. The First 
Report of The National Cancer Registry Cancer 
Incidence in Malaysia. July 2003 ed.
Molina, R., Segui, M.A., Climent, M.A., Bellmunt, 
J., Albanelll, J., Fernandez, M., Filella, X., Jo, J., 
Gimenez, N., Iglesias, E., Miralles, M., Alonso, 
C., Peiro, G., Perez-Picanol, E. & Ballesta, A. M. 
1998. p53 oncoprotein as a prognostic indicator 
in patients with breast cancer. Anticancer Res 
18(1B): 507-511.
Nohara, T., Ryo, T., Iwamoto, S., Gon, G. & Tanigawa, 
N. 2001. Expression of cell-cycle regulator p27 
is correlated to the prognosis and ER expression 
in breast carcinoma patients. Oncology 60(1): 
94-100.
Osborne, R.J., Merlo, G.R., Mitsudomi, T., Venesio, 
T., Liscia, D.S., Cappa, A.P., Chiba, I., Takahashi, 
T., Nau, M.M., Callahan, R. & Et Al. 1991. 
Mutations in the p53 gene in primary human 
breast cancers. Cancer Res 51(22): 6194-6198.
Poller, D. N., Roberts, E. C., Bell, J. A., Elston, C. W., 
Blamey, R. W. & Ellis, I. O. 1993. p53 protein 
expression in mammary ductal carcinoma 
in situ: relationship to immunohistochemical 
expression of estrogen receptor and c-erbB-2 
protein. Hum Pathol 24(5): 463-468.
Schmitt, F.C., Leal, C. & Lopes, C. 1995. p53 protein 
expression and nuclear DNA content in breast 
intraductal proliferations. J Pathol 176(3): 233-241.
Sgambato, A., Migaldi, M., Leocata, P., Ventura, L., 
Criscuolo, M., Di Giacomo, C., Capelli, G., 
Cittadini, A. & De Gaetani, C. 2000. Loss of 
p27Kip1 expression is a strong independent 
prognostic factor of reduced survival in N0 
gastric carcinomas. Cancer.  89(11): 2247-2257.
Silvestrini, R., Benini, E., Daidone, M.G., Veneroni, 
S., Boracchi, P., Cappelletti, V., Di Fronzo, G. 
& Veronesi, U. 1993. p53 as an independent 
prognostic marker in lymph node-negative 
breast cancer patients. J Natl Cancer Inst 85(12): 
965-970.
Silvestrini, R., Veneroni, S., Daidone, M.G., Benini, 
E., Boracchi, P., Mezzetti, M., Di Fronzo, G., 
Rilke, F. & Veronesi, U. 1994. The Bcl-2 protein: 
a prognostic indicator strongly related to p53 
protein in lymph node-negative breast cancer 
patients. J Natl Cancer Inst 86(7): 499-504.
Simon, R. & Altman, D.G. 1994. Statistical aspects 
of prognostic factor studies in oncology. Br J 
Cancer. 69(6): 979-685.
Thor, A.D., Moore, D.H., Ii, Edgerton, S.M., Kawasaki, 
E.S., Reihsaus, E., Lynch, H.T., Marcus, J.N., 
Schwartz, L., Chen, L.C., Mayall, B.H. & Et Al. 
1992. Accumulation of p53 tumor suppressor 
gene protein: an independent marker of 
prognosis in breast cancers. J Natl Cancer Inst 
84(11): 845-855.
Walker, R.A., Dearing, S.J., Lane, D.P. & Varley, J.M. 
1991. Expression of p53 protein in infiltrating 
and in-situ breast carcinomas. J Pathol 165(3): 
203-211.
Watson, A.J., Merritt, A.J., Jones, L.S., Askew, 
J.N., Anderson, E., Becciolini, A., Balzi, M., 
Potten, C.S. & Hickman, J.A. 1996. Evidence 
of reciprocity of bcl-2 and p53 expression in 
human colorectal adenomas and carcinomas. 
Br J Cancer. 73(8): 889-895.
Zhang, G.J., Kimijima, I., Abe, R., Kanno, M., 
Katagata, N., Hara, K., Watanabe, T. & Tsuchiya, 
A. 1997. Correlation between the expression of 
apoptosis-related bcl-2 and p53 oncoproteins 
and the carcinogenesis and progression of 
breast carcinomas. Clin Cancer Res 3(12 Pt 1): 
2329-2335.
